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Intravenous 1,25 dihydroxycholecalciferol corrects glucose
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USA
Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance
in hemodialysis patients. The effects of intravenous 1,25 dihydroxycho-
lecalciferol [(OH)2D3} on glucose tolerance and insulin secretion were
studied in eleven uremic patients on regular hemodialysis and compared
with eleven healthy controls. Intravenous glucose tolerance tests
(IVGTT) were used to assess glucose tolerance, and the hyperglycemic
clamp technique was used to quantitate endogenous insulin secretion.
Three days after they had discontinued oral I ,25(OH)2D3, the dialysis
patients were then studied with (+D) and without (—D) a single
intravenous dose of 1 ,25(OH)2D3 at 2 sg/m2, given two hours before the
IVGTT or clamp studies. During the —D studies, the uremic patients
were glucose intolerant but not hyperinsulinemic. Intravenous
I ,25(OH)2D3 in dialysis patients increased glucose uptake (K values)
during IVGTT by 38% (P < 0.02) and increased early component of
insulin secretion during hyperglycemic clamps by 48% (P < 0.01) and
the late component by 32% (P <0.01). After intravenous l,25(OH)2D3,
the dialysis patients became hyperinsulinemic and regained glucose
tolerance. Intravenous 1 ,25(OH)2D3 did not change the K values during
IVGTT nor the insulin secretion during hyperglycemic clamps in the
control subjects. During the —D studies, serum concentrations of
1 ,25(OH)2D3 were significantly lower in uremic patients compared with
controls. Serum l,25(OH)2D3 during the +D studies increased to
supraphysiological levels in both uremic patients and controls. Serum
concentrations of intact parathyroid hormone, total and ionized cal-
cium, magnesium, potassium, urea nitrogen and creatinine were not
different between the +D and —D studies in neither the uremic patients
nor the controls. These results suggest that 1,25(OH)2D3 deficiency,
independent of parathyroid hormone and calcium, may contribute to
the abnormalities in glucose tolerance and insulin secretion in dialysis
patients.
Abnormal carbohydrate metabolism in patients with end-
stage renal disease has been recognized for 80 years [1]. Insulin
resistance is almost universal among uremic patients [2, 3].
There are, however, two distinguishable subgroups of uremic
patients with regard to glucose tolerance. About half of uremic
patients can augment their insulin secretion sufficiently to
maintain normal glucose tolerance despite insulin resistance. In
the other half of uremic patients, insulin secretion following
glucose loads is not different from normal values, so that
glucose intolerance results [2]. The mechanism responsible for
Received for publication July 22, 1991
and in revised form October 28, 1991
Accepted for publication October 28, 1991
© 1992 by the International Society of Nephrology
the inhibition of insulin secretion in the second group of uremic
patients is not understood.
There is recent evidence that elevated circulating concentra-
tions of parathyroid hormone (PTH) may inhibit insulin secre-
tion in uremia. PTH concentrations correlate inversely with
glucose tolerance in adolescents with chronic renal insuffi-
ciency [4]. Insulin hypersecretion in response to a glucose load
occurs only in those uremic patients with normal PTH concen-
trations [5]. In one study, glucose tolerance and insulin secre-
tion were studied in uremic patients on hemodialysis with
uncontrollable hyperparathyroidism before and after subtotal
parathyroidectomy [4]. Preoperatively, all the patients had high
amino terminal PTH concentrations; they also had insulin
resistance with no compensatory increase in insulin secretion
following a glucose load, hence glucose intolerance. Following
surgical correction of their hyperparathyroidism, insulin resis-
tance persisted but insulin secretion in response to a glucose
load increased and glucose intolerance resolved. This study
suggests that PTH inhibits insulin secretion in uremic patients.
The role of vitamin D repletion was not separately assessed,
however, since these patients were supplemented with high
doses of vitamin D postoperatively [4]. Thus either hyperpara-
thyroidism or vitamin deficiency may have inhibited insulin
secretion in uremia. The present study was designed to examine
the individual contribution of 1 ,25(OH)2D3 to the modulation of
insulin secretion and glucose tolerance in patients with end-
stage renal disease.
Methods
Glucose metabolism was studied in 11 patients (aged 16 to 22
years) with end-stage renal disease and in 11 normal volunteers
(aged 17 to 23 years). The uremic patients had been on
maintenance hemodialysis three times a week for more than
three months. The patients and normal volunteers were all
within 20% of their ideal weight for height and had no evidence
or family history of diabetes mellitus. All the patients were
receiving oral l,25(OH)2D3, calcium carbonate and water-
soluble vitamin supplements (Nephrovite). The normal volun-
teers received no medications. All patients and controls in-
gested weight maintaining diets containing more than 200 g/day
of carbohydrate for at least three days prior to the study.
Sodium (3 g!day), potassium (3 g/day) and phosphorus (800
mg/day) were restricted in the diets of the uremic patients.
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Fluids were also restricted (600 mI/rn2) in the patients. None of
the normal volunteers were on restricted diets,
The patients had received oral 1 ,25(OH)2D3 (Rocaltrol, mean
dose 0.68 pg/day) for more than three months prior to the study.
The patients underwent paired studies one week apart so that
they were studied at the same point in their dialysis cycle (18 to
56 hours after their last dialysis session). Oral 1 ,25(OH)2D3 was
discontinued three days before each study and restarted after
the study. For one of the paired studies the patient remained in
the vitamin D withdrawn state (—D). In the other of the paired
studies, the patients received a single intravenous dose of
1 ,25(OH)2D3 (Calcijex; Abbot Laboratories, North Chicago,
Illinois, USA) at 2 agIm2 two hours prior to the study (+D).
One half of the patients underwent —D studies first, and the
other half underwent +D studies first. In order to maintain
normocalcemia while the patients were withdrawn from oral
1 ,25(OH)D3, the calcium concentration of the dialysate bath
was temporarily increased during the dialysis sessions.
All studies were performed in the morning, after an overnight
fast of 10 to 12 hours. Two intravenous catheters were inserted.
One catheter was placed in an antecubital vein for administra-
tion of test substances. In the dialysis patients, the second
catheter was placed in arteriovenous fistulae in the contralateral
forearm for sampling of arterial blood. In the controls, the
second catheter was placed in a vein of the hand or distal
forearm of the contralateral arm for blood sampling. The hand
chosen for blood sampling in the controls was placed in a heated
box (65°C) to "arterialize" the blood [6]. Six of the patients and
six healthy controls underwent paired —D and +D studies using
the IVGTT for assessment of glucose tolerance. The IVGTT
were performed as follows: after the collection of three baseline
blood samples for fasting glucose and insulin, glucose (0.5 g/kg
of body wt given as a solution of 50% dextrose in water) was
infused intravenously over two minutes. Blood samples were
obtained at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80 and 90 minutes
after the glucose load for plasma glucose determination. In
addition, seven patients and seven healthy controls underwent
hyperglycemic clamp studies (—D and +D) for assessment of
insulin secretion during constant hyperglycemia [7]. The hyper-
glycemic clamp technique was performed as previously de-
scribed [3, 7]. A bolus intravenous infusion of 20% dextrose
was given to achieve hyperglycemia at a plasma glucose con-
centration of 125 mg/dl above fasting levels. Constant hyper-
glycemia was then maintained for 120 minutes by measuring
plasma glucose every five minutes and by varying the intrave-
nous infusion rate of 20% dextrose. Under these conditions of
constant hyperglycemia, the mean plasma insulin concentration
from two to ten minutes (determined at 2 mm intervals) reflects
early insulin secretion (le) while the mean plasma insulin
concentration from 20 to 120 minutes (determined at 10 mm
intervals) reflects late insulin secretion (I). During either —D or
+D [2 hours after intravenous l,25(OH)2D3] studies, blood was
obtained at the beginning of either the IVGTT or the hypergly-
cemic clamp study for measurement of serum 1 ,25(OH)2D3,
intact PTH, fasting glucose, fasting insulin, ionized and total
calcium, phosphorus, potassium, magnesium, urea nitrogen and
creatinine.
Plasma glucose concentration was measured by the glucose
oxidase method using a Yellow Springs 23 AM glucose analyzer
(Yellow Springs Instruments, Yellow Springs, Ohio, USA).
Serum immunoreactive insulin was measured by double anti-
body radioimmunoassay (Pharmacia, Uppsala, Sweden). Se-
rum PTH was measured by an immunoradiometric assay for the
intact molecule (Incstar, Stillwater, Minnesota, USA). The
serum I ,25(OH)2D3 assay is specific for both 1 ,25(OH)2D3 and
1 ,25(OH)2D. This method involved a preliminary extraction
and purification of serum using a single column containing a
C180H activated matrix. Once purified, the material was quan-
titated in a radioreceptor assay using a calf thymus receptor and
tritiated l,25(OH)2D3. Separation of bound from free
1 ,25(OH)2D3 was achieved by incubation with dextran-coated
charcoal (Incstar, Stillwater, Minnesota, USA). Serum ionized
calcium was measured by an ion specific electrode (Nova
Biochemical, Massachusetts, USA). Serum total calcium, phos-
phorus, potassium and magnesium were measured by standard
methods on a multichannel autoanalyzer.
The study was approved by the Committee of Clinical Inves-
tigation, Childrens Hospital of Los Angeles. The purpose and
potential risks of the study were carefully explained to all
subjects and written informed consent was obtained before
their participation. All values are expressed as the mean
standard error of the mean. The data were tested for normality
using the chi square method. Student's f-test, paired and
unpaired as appropriate, was used for the analysis of the
results.
Results
The intraassay and interassay coefficients of variation of the
insulin assays were 5.2% and 8.2%, respectively. The intraas-
say and interassay coefficients of variation of the PTH assays
were 7.2 and 9.3%, respectively. The intraassay and interassay
coefficients of variation of the l,25(OH)2D3 assays were 8.2 and
9.9%, respectively. Constant hyperglycemia was achieved in all
patients and normal subjects during the hyperglycemic clamp
studies. The mean intraassay coefficient of variation for plasma
glucose was 6.9 0.4% during the hyperglycemic studies. The
interassay coefficient of variation of early insulin secretion (le)
was 6.3% and of late insulin secretion (I) was 4.7% from five
repeated studies in one normal subject.
The serum biochemical parameters during the paired IVGTT
studies in the uremic patients on dialysis and controls are
summarized in Table 1. Serum 1,25 concentrations were lower
in urernic patients compared with controls during the —D
studies (P < 0.02). Serum intact PTH, phosphorus, magnesium,
creatinine and urea nitrogen were higher in the uremic patients
compared with controls during the —D studies (P < 0.02).
Serum 1 ,25(OH)2D3 concentrations increased significantly after
1 ,25(OH)2D5 administration in both patients and controls (P <
0.01). Apart from this, there were no significant differences in
any of the parameters measured between the —D and +D
studies. Biochemical parameters during the hyperglycemic
clamp studies in the uremic patients and controls are summa-
rized in Table 2. Again, apart from the l,25(OH)2D3 concentra-
tions, there were no significant differences in any of the paired
parameters measured between the —D and +D studies. Thus
the uremic patients were 1 ,25(OH)2D5 deficient compared with
controls during the —D studies, and the uremic patients
achieved supraphysiotogical levels of serum 1 ,25(OH)2D1 dur-
ing the +D studies.
Plasma glucose concentration profiles during the paired —D
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Uremic patients Normal controls
+D -D +D -D
1,25 DHCC 97.5 25.3 24.4 16ab 145±27.3 36 1•8b
pg/mi
PTH pg/mi 294 85.7 305 95.l 14.0 1.4 10.5 1.2
Fasting 95 1.5 98 1.8 97 1.1 95 1.7
glucose
mg/dl
Fasting 10.9 1.6 11.2 2.2 8.4 2.2 9.5 2.1
insulin
jsU/ml
Ionized Ca 4.6 0.4 4.7 0.3 4.8 0.4 4.6 0.4
mg/di
Total Ca 8.9 0.3 8.4 0.4 9.2 0.4 8.6 0.3
mg/dl
Phosphorus 7.1 1.0 7.3 Q9a 3.3 0.1 3.2 0.1
mg/dl
Magnesium 2.6 0.1 2.5 0.2 1.8 0.! 1.8 0.1
mg/di
Potassium 6.5 0.3 5.9 0.2 5.2 0.3 5.3 0.7
mEq/dl
Creatinine 13.7 1.1 13.3 1.3 1.0 0.4 0.9 0.!
mg/dl
Urea nitrogen 79 5.3 81.3 5•3a 13.5 1.6 11.0 0.8
mg/dl
and +D IVGTT in the uremic patients and control subjects are
shown in Figure 1. K values were calculated using the formula
K = (0.6931t) x 100% per minute; where t = time taken for
plasma glucose to fall from the peak to half the peak value [8}.
K values during the --D IVGTT in the uremic patients (1.08
80
60
100
I
Fig. 2. Early insulin secretion (Je), mean insulin concentration from 2
to 10 minutes (at 2 mm intervals) during the hyperglycemic clamp
studies. *Ie significantly increased during +D studies (P < 0.01
compared with —D values) in the uremic patients on hemodialysis. le
did not change during +D studies in controls. Symbols used are as
those in Figure 1.
0.13) were significantly lower (P <0.02) than the corresponding
values in controls (1.48 0.12). Thus during the —D studies,
the uremic patients were glucose intolerant. K values during
+D IVGTT in the uremic patients (1.49 0.15) increased
significantly (38%, P < 0.02), so that K values during +D
studies were no longer different between the uremic patients
and the normal controls. In other words, acute intravenous
1 ,25(OH)2D3 administration reversed glucose intolerance in
uremic patients. K values during the +D IVGTT (1.46 0.13)
were not different from the K values during the —D IVGTT in
the normal controls.
The changes in le and I values during the paired —D and +D
hyperglycemic clamp studies in the uremic patients and control
subjects are shown in Figures 2 and 3, respectively. le and I
increased significantly after l,25(OH)2D3 (48% and 32%, re-
spectively, P < 0.01 in both cases) from the corresponding
values during —D clamp studies in the uremic patients. During
—D studies, le and I in the uremic patients were not different
Table 1. Serum biochemical parameters in uremic patients on
hemodialysis and controls during IVGTT
Uremic patient
+D
191.4 23.9 20.0 13a,b 170.2 14.7
225 99.1 246 l07.6a
86.8 3.4 89 2.2
Normal controls c -o
+D -D
39.1 0•7b D).2
cuc
—
14.2 2.7 14.0 2.7
89±3.4 87±3.3 c W
0Q
1,25 DHCC
pg/mi
PTH pg/mi
Fasting
glucose
mg/dl
Fasting
insulin
isU/mi
Ionized Ca
mg/dl
Total Ca
mg/dl
Phosphorus
mg/dl
Magnesium
mg/dl
Potassium
mEq/dl
Creatinine
ng/dl
Urea nitrogen
mg/dl
16.0 2.1 12.4 2.8 13.0 1.8 11.3 1.1
4.7 0.4 4.6 0.3 4.7 0.3 4.8 0.3
400
300
200
100
0-
—10 0 10 20 30 40 50 60 70 80 90
Time, minutes
Fig. 1. Plasma glucose concentration profiles in uremic patients on
9.7 0.4 9.3 0.4 9.6 0.1 9.4 0.2 hemodialysis and normal controls with (+D) and without (—D) intra-
venous 1,25(OH)2D3. Symbols are: (0) dialysis patients —D; (•)
5.9 0.5 6.1 0.6a 4.1 0.1 4.0 0.1 dialysis patients +D; (A) controls —D; (A) controls +D.
2.3 0.1 2.1 0.1 1.9 0.1 1.8 0.1
5.5 0.5 5.2 0.3 4.8 0.4 4.8 0.5
12.7 1.1 13.0 0.9 0.9 0.1 0.8 0.1
83.0 5.8 81.0 94 12.3 1.3 11.8 0.4
a P < 0.02 compared with control —D studiesb P < 0.01 compared with +D studies
Table 2. Serum biochemical parameters in uremic patients on
hemodialysis and controls during hyperglycemic clamp studies
40
20
—D
a p < 0.02 compared with control —D studies
b P < 0.01 compared with +D studies
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Fig. 3. Late insulin secretion (I), mean insulin concentration from 20
to 120 minutes (at 10 mm intervals) during the hyperglycemic clamp
studies. *1 significantly increased during the +D studies (P < 0.01
compared with —D values) in the uremic patients on hemodialysis. I did
not change during +D studies in controls. Symbols are: (0) dialysis
patients —D; (•) dialysis patients +D; (A) controls —D; (A) controls
+D.
from the corresponding values in the control subjects. During
the +D clamp studies, on the other hand, Ic and I in the uremic
patients were significantly higher than the corresponding con-
trol values (P < 0.02 in both cases) indicating that uremic
patients were hyperinsulinemic in the 1 ,25(OH)2D3 repleted
state. le and I did not change during +D clamp studies in the
normal subjects.
Discussion
The results of the present study show that the uremic patients
on maintenance dialysis became I ,25(OH)2D3 deficient when
withdrawn from their oral 1 ,25(OH)2D3 supplements for three
days. This is expected considering the short haff life (about 16
hours) of 1 ,25(OH)2D3 supplements [9]. The serum 1 ,25(OH)2D3
concentrations in the uremic patients and the normal controls
are compatible with published values in the literature [101. In
this vitamin D deficient state, uremic patients were glucose
intolerant due to inhibition of insulin hypersecretion in the face
of insulin resistance, Acute intravenous 1 ,25(OH)2D3 adminis-
tration led to a significant increase in serum 1,25(OH)2D3
concentration in the uremic patients to above the normal range
in control subjects. The apparent difference in serum
1 ,25(OH)2D3 concentrations in the patients during IVGTT and
glucose clamps may be due to larger variations of the vitamin D
assay in the high range, In the 1,25(OH)2D3 repleted state,
uremic patients became glucose tolerant and hyperinsutinemic,
suggesting that the inhibition of insulin hypersecretion was
relieved by the acute intravenous administration of I ,25(OH)2D3.
Serum PTH concentrations, on the other hand, did not change,
These results are consistent with the hypothesis that vitamin D
deficiency was responsible for the induction of glucose intoler-
ance and the inhibition of insulin secretion in uremic patients.
However, since the serum 1 ,25(OH)2D3 levels are supraphysi-
ologic, a pharmacologic effect of the vitamin D metabolite in
counteracting the influence of hyperparathyroidism on glucose
metabolism cannot be ruled out.
The results from the present study in I ,25(OH)2D3 deficient
uremic patients are consistent with previous studies on insulin
secretion in vitamin D deficient animals with normal renal
function [11—151 which have suggested that vitamin D metabo-
lites regulate pancreatic insulin release. Vitamin D deficiency in
rats with normal renal function was found to inhibit insulin but
not glucagon secretion from the isolated perfused pancreas in
response to glucose and arginine [111. Dietary vitamin D
repletion in vitamin D depleted rats markedly improved insulin
secretion, while dietary intake of calcium and serum calcium
concentrations played a lesser role in mediating insulin secre-
tion [12]. 1,25(OH)2D3, but not other vitamin D metabolites,
seems to play an essential role in the modulation of insulin
secretion regardless of the dietary caloric intake and prevailing
serum calcium concentrations [13]. Furthermore, IVGTT in
vitamin D depleted rats revealed glucose intolerance associated
with reduced in vivo insulin secretion following glucose loads
[14]. Acute intravenous administration of l,25(OH)2D3 in-
creased insulin secretion and corrected glucose intolerance in
vitamin D depleted animals [141.
Further evidence from animal studies suggests that the endo-
crine pancreas is also a target tissue for l,25(OH)2D3, the active
vitamin D metabolite. A cytosol receptor protein for
l,25(OH)2D3 has been identified in the chick pancreas [15, 16].
The presence of immunoreactive vitamin D-dependent calcium
binding protein (CaBP) has been demonstrated in the pancreas
of the chick [151, pig [171 and rat [18] by radioimmunoassay.
CaBP has been localized by immunohistochemistry in the beta
cells of the chick [19], cat [20], dog [20], mice [20] and rat [20].
Furthermore, tritiated 1 ,25(OH)2D3 has been localized in the
nucleus of the rat pancreatic beta cell by autoradiography [211.
Collectively these results strongly support the involvement of
l,25(OH)2D3 in the regulation of insulin secretion.
In the present study, the increase in insulin secretion and the
correction of glucose intolerance in the hemodialysis patients
after acute intravenous I ,25(OH)2D3 occurred without signifi-
cant changes in serum intact PTH concentrations. Although
previous studies have suggested a role for hyperparathyroidism
in the induction of glucose intolerance and the inhibition of
insulin secretion, the evidence is conflicting. PTH has been
reported to increase, decrease or have no effect on insulin
secretion [22—251, Patients with primary hyperparathyroidism
may have glucose intolerance [22, 23]. Elevated plasma insulin
levels both in fasting state and in response to glucose have been
reported in these patients, suggesting that the presence of
insulin resistance and parathyroidectomy led to significant
reduction in hyperinsulinemia [22]. It is possible though that
insulin resistance and hyperinsulinemia in such cases is a result
of the hypercalcemia rather than hyperparathyroidism per se.
Indeed, the mechanism of glucose tolerance in patients with
primary hyperparathyroidism may be different since these
individuals do not have low circulating levels of 1 ,25(OH)2D as
ui-ernie patients. Acute intravenous infusion of PTH (over 3
hours) had no effect on serum calcium in human volunteers, and
it did not alter plasma glucose or insulin responses during oral
glucose tolerance tests or intravenous tolbutamide tolerance
tests. However, chronic intramuscular administration of PTH
(over 8 days) to human volunteers caused both hypercalcemia
I
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and hyperinsulinemia in response to oral glucose and intrave-
nous tolbutamide seen in patients with primary hyperparathy-
roidism [22]. Acute PTH administration in hypophosphatemic
dogs had no effect on glucose tolerance or insulin responses to
oral glucose and intravenous tolbutamide [24]. Chronic intra-
peritoneal administration of PTH to rats coupled with dietary
manipulation to prevent hypercalcemia decreased glucose-stim-
ulated insulin release from isolated islets [25]. The difference in
insulin secretion following chronic versus acute administration
of PTH may be mediated by different intracellular calcium and
phosphorus responses in the beta cell [25].
Changes in glucose metabolism similar to those observed in
the present study have been achieved in uremic patients in two
previous studies by surgical [4] or medical [5] correction of
hyperparathyroidism. Unfortunately, the effect of vitamin D
deficiency was not separately assessed in these two studies.
Indeed the patients who had parathyroidectomy were started on
high doses of 1 alpha hydroxycholecalciferol supplements post-
operatively [4], and the patients who were treated medically
were shown to demonstrate a significant increase in their serum
1,25(OH)2D3 concentrations following phosphorus restriction
[26]. Thus it could not be determined whether hyperparathy-
roidism or vitamin D deficiency was the factor inhibiting insulin
secretion in these uremic patients.
Two studies in uremic animals had been performed to address
the role of PTH in the pathogenesis of insulin abnormalities in
uremia. Akmal and colleagues examined the effect of hyper-
parathyroidism in a uremic parathyroidectomized dog model
[27]. Insulin resistance was present in all uremic dogs. How-
ever, only uremic dogs with intact parathyroids were glucose
intolerant; uremic parathyroidectomized dogs were glucose
tolerant. Glucose-mediated insulin responses were greater in
uremic parathyroidectomized dogs than uremic dogs with intact
parathyroids and secondary hyperparathyroidism. The authors
postulated that excess PTH in uremia interfered with the ability
of the pancreatic beta cells to augment insulin secretion appro-
priately in response to the insulin resistant state. Fadda and
colleagues [251 studied beta cell function of isolated pancreatic
islets in uremic rats and found significant inhibition of insulin
release in uremia. However, insulin release from islets of
parathyroidectomized uremic rats was not different from con-
trol rats. The effect of hyperparathyroidism on insulin secretion
was not related to alterations in cyclic adenosine monophos-
phate and the authors postulated that the mechanism might be
due to calcium accumulation in the pancreas. Changes in the
serum concentrations of calcium [23, 26], phosphorus [24, 271,
magnesium [29, 30] or potassium [291 may affect insulin secre-
tion. The difference in the insulin response to hyperglycemia in
the present study could not be attributed to differences in
plasma concentrations of these electrolytes which were not
different in the —D and +D studies. Also, the effect of acute
intravenous 1 ,25(OH)2D3 administration is independent of the
state of uremia since the blood urea nitrogen and serum
creatinine concentrations were the same during the —D and +D
studies.
In summary, acute intravenous 1,25(OH)2D1 administration
to vitamin D withdrawn hemodialysis patients increased insulin
secretion and corrected glucose intolerance. These changes in
carbohydrate metabolism occurred without significant changes
in serum intact PTH, ionized or total calcium, phosphorus,
magnesium, potassium, creatinine and blood urea nitrogen.
Thus I ,25(OH)2D3, independent of PTH and serum electrolyte
concentrations, appears to be an important acute modulator of
insulin release from the pancreatic beta cell in uremia.
1 ,25(OH)2D3 deficiency may contribute to carbohydrate de-
rangements in chronic uremia. Alternatively, l,25(OH)2D3 may
exert pharmacologic effects in correcting the abnormalities in
glucose metabolism in patients with end-stage renal disease.
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